Physiologically-based Pharmacokinetic Modeling of Target-Mediated Drug Disposition of Bortezomib in Mice

por Zhang, Li, Mager, Donald E.
Publicado en J Pharmacokinet Pharmacodyn (2015)

Calculated Log D is Inversely Correlated with Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts

por Nanavati, Charvi, Mager, Donald E.
Publicado en J Pharm Sci (2016)

Population pharmacokinetics of exenatide

por Cirincione, Brenda, Mager, Donald E.
Publicado en Br J Clin Pharmacol (2016)

Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells

por Nanavati, Charvi, Mager, Donald E.
Publicado en Pharm Res (2017)

Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

por Ramakrishnan, Vidya, Mager, Donald E.
Publicado en J Pharmacol Exp Ther (2018)

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma

por Ramakrishnan, Vidya, Mager, Donald E.
Publicado en CPT Pharmacometrics Syst Pharmacol (2018)

Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients

por Zhang, Li, Mager, Donald E.
Publicado en J Pharm Sci (2018)

Bridging Pharmacology and Pathophysiology via Systems Modeling

por D’Argenio, David Z., Mager, Donald E.
Publicado 2010

Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

por Yan, Xiaoyu, Mager, Donald E., Krzyzanski, Wojciech
Publicado 2009

Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics

por Chen, Ting, Mager, Donald E., Kagan, Leonid
Publicado 2012

Population Pharmacodynamic Modeling of Exenatide after Two-week Treatment in STZ/NA Diabetic Rats

por Chen, Ting, Kagan, Leonid, Mager, Donald E.
Publicado 2013

Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats

por Kagan, Leonid, Zhao, Jie, Mager, Donald E.
Publicado en Pharm Res (2014)

Influence of Meals and Glycemic Changes on QT Interval Dynamics

por Cirincione, Brenda, Sager, Philip T., Mager, Donald E.
Publicado en J Clin Pharmacol (2017)

Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts

por Nanavati, Charvi, Ruszaj, Donna, Mager, Donald E.
Publicado en CPT Pharmacometrics Syst Pharmacol (2017)

Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

por Marathe, Anshu, Peterson, Mark C., Mager, Donald E.
Publicado 2008

Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition

por Abraham, Anson K., Krzyzanski, Wojciech, Mager, Donald E.
Publicado 2007

Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems

por Yang, Jun, Mager, Donald E., Straubinger, Robert M.
Publicado 2009

Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition

por Marathe, Anshu, Van Wart, Scott, Mager, Donald E.
Publicado 2010

Integrated Model for Denosumab and Ibandronate Pharmacodynamics in Postmenopausal Women

por Marathe, Dhananjay D., Marathe, Anshu, Mager, Donald E.
Publicado 2011

Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans

por Mager, Donald E., Woo, Sukyung, Jusko, William J.
Publicado 2009